Shares of Perrigo (NYSE: PRGO ) , one of the world's largest health care suppliers, slid with the broader market on Aug. 15 after the company reported fourth-quarter earnings that topped analyst estimates but missed revenue forecasts. Over the past month, Perrigo has drawn a lot of criticism for its $8.6 billion takeover of Irish pharmaceutical Elan Corporation (UNKNOWN: ELN.DL2 ) , which reduced its corporate tax rate by moving its headquarters from Michigan to Ireland. I discussed the controversial Elan acquisition at length in a previous article, so in this article, I'd like to focus more on Perrigo's fundamentals.
Mixed fourth-quarter and full-year earnings
For its fourth quarter, Perrigo earned $1.57 per share, a 22.7% increase over the prior year quarter that beat the consensus estimate by a penny. Revenue rose 16.3% to $967.2 million, but fell short of the $999 million that analysts had expected. The company's full year results were similar -- earnings of $5.61 per share, which topped estimates by a penny, and revenue of $3.5 billion, which missed the consensus estimate of $3.6 billion. Full-year earnings and revenue rose 12.4% and 12%, respectively.
Much of Perrigo's top line growth during the quarter was attributed to its recent acquisitions of four companies -- Sergeant's Pet Care Products, pet care products maker Velcera, prescription drug maker Rosemont Pharmaceuticals and eye-care company Fera Pharmaceuticals -- which generated a combined $83 million in sales during the quarter. New products contributed to $30 million in new sales, and Perrigo's base business grew by $21 million.
Growth in consumer health care
Perrigo's consumer health care unit is its largest business segment, accounting for 58% of the company's top line with $563 million in sales. Revenue at the segment -- which covers a range of over-the-counter and generic medications, dietary products, and feminine hygiene products -- rose 16% from the prior-year quarter. The inclusion of Sergeant's Pet Care Products and Velcera aided this segment's growth.
Perrigo reported the strongest growth in the cough and cold unit and its smoking cessation unit, which produces nicotine gum and lozenges. Perrigo competes against Johnson & Johnson (NYSE: JNJ ) and GlaxoSmithKline (NYSE: GSK ) in both categories. Johnson & Johnson owns Nicorette, the most well-known smoking cessation product on the market. J&J markets the product in international markets, focusing extensively on emerging markets like India, which have a high percentage of smokers. Glaxo holds the license to Nicorette within the United States, which complements its own Commit nicotine lozenges.
J&J and Glaxo both have extensive OTC portfolios. J&J produces Tylenol, while Glaxo manufactures Panadol -- two of the most popular OTC cold and pain medications in the world. Perrigo, on the other hand, has built its business on selling generic store-brand versions of popular treatments from J&J, Glaxo, and other pharmaceutical companies at lower prices. Perrigo's OTC sales were also boosted by J&J's ongoing manufacturing problems at McNeil, its OTC unit that was hit by a wave of recalls in 2010.
Although Perrigo faces stiff competition from J&J and Glaxo in consumer health care, its 16% sales growth last quarter is comfortably outpacing both companies. Last quarter, J&J's consumer health care revenue, which accounts for 21% of its top line, only rose 1.1% year-on-year. Meanwhile, Glaxo reported 2% sales growth in consumer health care, which comprises 20% of its top line.
Growth in generics
Perrigo's second largest business segment is its Rx Pharmaceuticals segment, which accounts for 20% of its total revenue. Sales at this segment rose 24% year-on-year to $195 million, aided by the aforementioned acquisitions of Rosemont and Fera, which contributed $16 million to its top line. Perrigo is the largest maker of generic drugs for the major retail chains in the United States, including Wal-Mart and Walgreen.
Perrigo recently announced a promising new partnership with generics rival Teva Pharmaceutical (NYSE: TEVA ) to launch a generic version of Temodar, a brain cancer drug from Merck. Temodar generated $423 million in U.S. sales for Merck in 2012, and would be a valuable addition to both Perrigo and Teva's drug portfolios.
Teva might need that sales boost more than Perrigo, however, based on Teva's mediocre sales growth last quarter. During the second quarter, Teva's generic businesses in the United States and Europe respectively declined 8% and 5% from the prior year quarter. Teva blamed lower sales of generic Lexapro, an antidepressant, and Avapro, a high blood pressure medication, for its top line decline in the United States. It stated that macro problems caused sales to decline in Europe.
Although Perrigo's 24% growth in generics is impressive by comparison, it still pales in comparison to Actavis, which reported a 58% increase in generic sales last quarter, thanks to strong sales of generic Zovirax (treatment for herpes), Yaz (birth control) and Viagra (treatment for erectile dysfunction).
Other businesses and the road ahead
Sales at Perrigo's other two smaller business segments -- nutritional products and active pharmaceutical ingredients -- rose 11% and 6%, respectively. The company reported strong sales of vitamins, minerals, and supplements in the former and a favorable product mix in the latter.
Perrigo investors are anticipating big gains from its acquisition of Elan, which will reduce its corporate tax rate from 35% to 12.5%. In addition, it will gain royalties from Elan's multiple sclerosis drug Tysabri. In February, Elan sold off most of its rights to Tysabri, which is marketed by Biogen Idec, back to Biogen for $3.25 billion, but it still retains 25% of the rights to future royalties of the drug, which generated $1.6 billion in sales last year.
Those two factors are expected to boost Perrigo's adjusted fiscal 2014 earnings by at least $0.10 per share, and its 2015 earnings by $0.70 to $0.80 per share. With the Elan acquisition factored in, the company expects to earn $6.35 to $6.60 per share for fiscal 2014, a 13% to 18% year-on-year gain that still falls short of the consensus estimate of $6.67 per share.
The Foolish bottom line
Perrigo is a fairly strong investment on its own, even without factoring in the controversial Elan acquisition. The company's revenue growth in consumer health care is outpacing its much larger rivals, and it is performing admirably in the generics business. Although the company is coming in a bit light in terms of quarterly revenue growth and full year earnings, its top line will likely continue growing in the double digits as its industry peers struggle to even hit the high single digits.
Even with this acquisition, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.